Exclusive agreement with Jamjoom Pharma covers commercialization and distribution of QUVIVIQ™ (daridorexant) in Saudi Arabia and the Levant region

Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Jamjoom Pharmaceuticals Factory Co. (“Jamjoom Pharma”) for the distribution and commercialization of QUVIVIQ™ (daridorexant), Idorsia’s treatment for adults with insomnia, in Saudi Arabia and the Levant region.

Benjamin Limal, President of Europe & International Markets for Idorsia, commented:
“We are delighted to partner with Jamjoom Pharma, a leading pharmaceutical company in Saudi Arabia and the Levant region. With Jamjoom’s strong market presence, deep regulatory expertise, and well-established commercial infrastructure, Jamjoom Pharma is ideally positioned to support the successful launch and broad access of our innovative insomnia treatment. As we continue to execute our international growth strategy for QUVIVIQ, partnerships such as this are instrumental in expanding commercialization across new geographies and maximizing patient access globally.”

Tarek Hosni, CEO of Jamjoom Pharma, commented: 
"We are proud to partner with Idorsia to bring QUVIVIQ to patients across Saudi Arabia and the Levant. This collaboration aligns with our commitment to expanding access to innovative, high-quality therapies in areas of significant unmet medical need. Leveraging our extensive commercial and market access capabilities, as well as our strong regional footprint, we look forward to supporting the successful introduction of QUVIVIQ and improving the lives of patients suffering from insomnia."

Under the terms of the agreement, Idorsia will receive an upfront payment and is eligible to receive additional payments, including royalties on net sales. Jamjoom Pharma will hold the marketing authorization for QUVIVIQ in Saudi Arabia and will be responsible for regulatory, distribution, promotion, and commercialization activities across Saudi Arabia and the Levant region. Idorsia will supply finished drug product for the agreed territories.

QUVIVIQ – a different kind of insomnia treatment
Insomnia affects millions worldwide, yet commonly used treatments can lead to next-day drowsiness, dependence, and withdrawal symptoms – leaving a clear unmet need for safer, effective alternatives.

Discovered by Idorsia, QUVIVIQ works differently from traditional hypnotics. As a dual orexin receptor antagonist, it selectively targets the orexin system, helping to regulate overactive wake signaling without broadly suppressing brain activity. Its optimized pharmacokinetics promote restorative sleep throughout the entire night, reducing morning sleepiness and improving daytime functioning.

Clinical trials published in The Lancet Neurology demonstrated that daridorexant significantly improved sleep onset, sleep maintenance, and self-reported total sleep time at 25mg and 50mg doses compared to placebo. Daridorexant 50 mg also demonstrated a highly significant improvement in daytime functioning compared to placebo.

Global availability
QUVIVIQ is marketed by Idorsia in North America and Europe, and is available in key international markets in Asia-Pacific and the Middle East through commercial partnerships. Idorsia also has a license and supply agreement for Latin America. This collaboration with Jamjoom Pharma further strengthens Idorsia’s commitment to building QUVIVIQ into a global brand.